InViragen Initiates a Phase 2 Clinical Study of DENVax, a Recombinant, Tetravalent Dengue Vaccine

FORT COLLINS, Colo.--(BUSINESS WIRE)--Inviragen, Inc. today announced the initiation of a Phase 2, randomized, double-blind, placebo-controlled study of DENVax, the Company’s investigational dengue vaccine. The Phase 2 trial will test the safety and immunogenicity of DENVax in multiple age groups in dengue endemic countries. The initiation of this Phase 2 study follows the successful conclusion of a Phase 1 study of DENVax that was conducted in Colombia in collaboration with PECET, the Program for the Study and Control of Tropical Diseases at Universidad de Antioquia. Data from this Phase 1 study demonstrate that the vaccine is safe and well-tolerated and immunogenic in dengue-naive adults; the results will be presented at the annual meeting of the American Society of Tropical Medicine and Hygiene (ASTMH) on December 7, 2011 in Philadelphia, PA.